Items where authors include "Worm, M."

Article

Pereira, M.P., Stevanovic, K., Kocatürk, E. et al. (32 more authors) (2025) International survey of treatment practices for atopic dermatitis in pregnant and breastfeeding women: Physician perspectives. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. ISSN 1610-0379

Kosloski, M.P. orcid.org/0000-0002-6642-2439, Guttman‐Yassky, E. orcid.org/0000-0002-9363-324X, Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (13 more authors) (2024) Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials. Clinical and Translational Science, 17 (8). e13874. ISSN 1752-8054

Zuberbier, T. orcid.org/0000-0002-1466-8875, Abdul Latiff, A., Aggelidis, X. orcid.org/0000-0003-1715-3022 et al. (105 more authors) (2023) A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative. Clinical and Translational Allergy, 13 (9). e12299. ISSN 2045-7022

Zuberbier, T. orcid.org/0000-0002-1466-8875, Beck, L.A., Bedbrook, A. et al. (12 more authors) (2023) Developing integrated care pathways for atopic dermatitis—challenges and unmet needs. Clinical and Translational Allergy, 13 (3). e12236. ISSN 2045-7022

Ring, J., Worm, M., Wollenberg, A. et al. (35 more authors) (2021) Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 35 (6). e362-e365. ISSN 0926-9959

Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E. et al. (19 more authors) (2021) Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). British Journal of Dermatology, 184 (3). pp. 437-449. ISSN 0007-0963

Simpson, E.L., Bieber, T., Guttman-Yassky, E. et al. (23 more authors) (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. The New England Journal of Medicine. ISSN 0028-4793